Perrigo Company plc, through its subsidiaries, operates as an over-the-counter (OTC) consumer goods and specialty pharmaceutical company worldwide. The company operates as a manufacturer of OTC healthcare products and supplier of infant formulas for the store brand market. The company also provides generic extended topical prescription products, and receives royalties from the sale of the multiple sclerosis drug, Tysabri. The company provides ‘Quality Affordable Healthcare Products’ across various product categories and geographies, primarily in North America, Europe, and Australia, as well as in other markets, including Israel and China. Segments The company’s segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx Pharmaceuticals), Specialty Sciences, and Other. CHC This segment focuses primarily on the global sale of OTC store brand products, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, Vitamins, Minerals and Supplements (VMS), animal health, and diagnostic products. The company serves the U.S., U.K., Mexico, and Australia. The company sells its CHC products to consumers through store brands or its own label brands. The CHC segment develops, manufactures, and markets products that are comparable in quality and effectiveness to national brands. The CHC segment also develops, manufactures, and distributes certain branded products when the strategy is synergistic with the company’s store brand business. Branded products include the Good Sense, Sergeant's, Sentry, Herron, and PetArmor value brands, and the ScarAway brand name. The company manufactures its products at its plants in the U.S., U.K., Mexico, Israel, and Australia, and it sources its remaining needs from third parties. The company relies on both internal R&D and strategic product development agreements with outside sources to develop new products. Sales and Marketing The company’s customers include major global, national, and regional retail drug, supermarket, and mass merchandise chains such as Walmart, CVS, Walgreens/Rite Aid, Kroger, Target, Dollar General, Sam’s Club, Costco, Petco, Petsmart, Boots (U.K.), Tesco (U.K.), ASDA (U.K.), Woolworth (Australia), Coles (Australia), and major wholesalers, including McKesson, Cardinal Health, and AmerisourceBergen. Competition The company’s primary competitors include manufacturers, such as LNK International, Inc., PL Developments, International Vitamin Corporation, and Dr. Reddy's Labs, and brand-name pharmaceutical and consumer product companies, such as Johnson & Johnson, Pfizer, Bayer AG, Nestle S.A. (Gerber), Abbott Nutrition, NBTY, and Mead Johnson Nutrition Co. BCH This segment develops, manufactures, markets, and distributes European OTC brands in the natural health and VMS, cough, cold and allergy, smoking cessation, personal care and derma-therapeutics, lifestyle, and anti-parasite categories. This segment distributes its products through a network of pharmacies in 36 countries, primarily in Europe. This segment focuses on building brands. The company sells products from approximately 300 brands both on its own and through third parties. The company launched a number of new BCH products in the six months ended December 31, 2015, most notably lifestyle products, such as XLS Max strength and cough and cold products, such as Bronchostop. The company owns Naturwohl, a Munich, Germany-based nutritional business known for its German dietary supplement brand, Yokebe. The portfolio included smoking cessation products, cold and flu treatments, pain relief products, nasal decongestants, and cold sore management products sold primarily in Europe. Both acquisitions built upon the global platform the company established through the Omega acquisition and expanded its market share in the European OTC market. Sales and Marketing The company’s customers include pharmacies, drug, and grocery stores located primarily in Europe, including Boots, ASDA, Tesco, DM, Rossmann, ETOS, and Kruidvat. The BCH segment sells its products through a pharmacy sa
perrigo co plc (PRGO:New York)
Lower Grand Canal Street
Phone: 353 1 709 4000
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for PRGO.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.